XEN D0501
Alternative Names: BAY-69-9426; XEND0501Latest Information Update: 30 Nov 2023
Price :
$50 *
At a glance
- Originator Xention
- Developer Ario Pharma; PILA PHARMA
- Class Antihyperglycaemics; Small molecules; Urologics
- Mechanism of Action TRPV1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
- Discontinued Cough; Overactive bladder
Most Recent Events
- 01 Jul 2022 XEN D0501 receives Orphan Drug status for Erythromelalgia in USA (Pila Pharma pipeline, November 2023)
- 10 Mar 2021 Phase II development is ongoing in Type-2 diabetes mellitus in Lithuania and Denmark (Pila Pharma pipeline, March 2021)
- 10 Mar 2021 Pila Pharma plans a phase IIb trial in Type-2 diabetes mellitus (PO) (Pila Pharma pipeline, March 2021)